# Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066

> **NCT03198767** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 54 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** LIK066
- **DIETARY_SUPPLEMENT:** Carbohydrate 50%
- **DIETARY_SUPPLEMENT:** Carbohydrate 25%
- **DIETARY_SUPPLEMENT:** Carbohydrate 8%
- **DIETARY_SUPPLEMENT:** Carbohydrate 0%
- **DIETARY_SUPPLEMENT:** Psyllium
- **DIETARY_SUPPLEMENT:** Calcium carbonate

## Key facts

- **NCT ID:** NCT03198767
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-21
- **Primary completion:** 2017-09-04
- **Final completion:** 2017-09-04
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03198767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03198767, "Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03198767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*